Sebastian M. Waldstein
Research Subjects
Sebastian M. Waldstein has a total of 136 co-authors. Here are the top co-authors by number of shared publications:
- Ursula Schmidt-Erfurth
Medical University of Vienna
31 shared publications - Bianca S. Gerendas
Medical University of Vienna
22 shared publications Christian Simader
Christian Doppler Laboratory for Ophthalmic Image Analysis, Vienna Reading Center, Department of Ophthalmology, Medical University of Vienna, Spitalgasse 23, 1090 Vienna, Austria
15 shared publications- Georg Langs
Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria
14 shared publications - Hrvoje Bogunović
Medical University of Vienna
14 shared publications Ursula Schmidt-Erfurth
Medical University of Vienna
10 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Journal of Ophthalmology
- Vol. 2026 (1)
The Clinical Significance of Imaging Biomarkers Discoverable by Anomaly Detection Methods in Retinal Diseases: A Review
Introduction: The increasing prevalence of vision‐threatening retinal diseases poses a growing challenge on healthcare systems worldwide, underscoring the need for effective strategies in disease diagnosis and management. Unsupervised artificial intelligence (AI) approaches, such as anomaly detection, offer the potential to identify established and novel retinal imaging biomarkers. They reduce reliance on expert‐driven annotations, mitigate bias, and overcome the limitations of predefined disease categories. Moreover, when integrated into clinical workflows, they have the potential to enhance practical applicability by supporting efficient screening, longitudinal disease monitoring, and objective assessment of treatment response. Areas Covered: This review examines the role of anomaly detection for discovering clinically relevant retinal imaging biomarkers, by categorizing biomarkers according to their underlying pathophysiology, summarizing the spectrum of anomaly detection methods applied in the field, and highlighting biomarkers that have been identified through these approaches. Critical Appraisal: Current anomaly detection methods favor the identification of established biomarkers characterized by strong intensity contrasts and well‐defined structural boundaries, while more subtle abnormalities remain difficult to capture. Future research should prioritize integrating large language models (LLMs), foundation methods, multimodality, and few‐shot anomaly detection, and increase explainability to advance the clinical application of anomaly detection for retinal imaging biomarker discovery in ophthalmology.
- 1 January 2026
- Published by Wiley in Journal of Ophthalmology
- Vol. 2026 (1)
Open AccessThe Clinical Significance of Imaging Biomarkers Discoverable by Anomaly Detection Methods in Retinal Diseases: A Review
Introduction: The increasing prevalence of vision‐threatening retinal diseases poses a growing challenge on healthcare systems worldwide, underscoring the need for effective strategies in disease diagnosis and management. Unsupervised artificial intelligence (AI) approaches, such as anomaly detection, offer the potential to identify established and novel retinal imaging biomarkers. They reduce reliance on expert‐driven annotations, mitigate bias, and overcome the limitations of predefined disease categories. Moreover, when integrated into clinical workflows, they have the potential to enhance practical applicability by supporting efficient screening, longitudinal disease monitoring, and objective assessment of treatment response. Areas Covered: This review examines the role of anomaly detection for discovering clinically relevant retinal imaging biomarkers, by categorizing biomarkers according to their underlying pathophysiology, summarizing the spectrum of anomaly detection methods applied in the field, and highlighting biomarkers that have been identified through these approaches. Critical Appraisal: Current anomaly detection methods favor the identification of established biomarkers characterized by strong intensity contrasts and well‐defined structural boundaries, while more subtle abnormalities remain difficult to capture. Future research should prioritize integrating large language models (LLMs), foundation methods, multimodality, and few‐shot anomaly detection, and increase explainability to advance the clinical application of anomaly detection for retinal imaging biomarker discovery in ophthalmology.
- Open Access
- 25 April 2025
- Published by Springer Nature in Wiener Medizinische Wochenschrift
- Vol. 175 (7-8) , 141-142
Current trends in ophthalmology with an impact on medicine and society
- 25 April 2025
- Published by Springer Nature in Wiener Medizinische Wochenschrift
- Vol. 175 (7-8) , 141-142
Open AccessCurrent trends in ophthalmology with an impact on medicine and society
- 4 December 2024
- Published by Springer Nature in Eye
- Vol. 39 (5) , 943-950
Faricimab maintains substance integrity and sterility after compounding and storage in two different polypropylene syringe types
Background Compounding and storage of intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents in syringes is commonly performed in an off-label manner. However, the preservation of compound integrity and microbiological safety must be guaranteed. The aim of this study was to compare the chemical and physical stability, sterility and binding affinity to vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) of faricimab, a novel bispecific anti-VEGF/Ang-2 biologic, after compounding and storage in two different polypropylene syringe types for up to 28 days. Methods Faricimab was compounded into silicone oil-free and silicone oil-containing polypropylene syringes under controlled aseptic clean room conditions and stored under light protection at 2–8 °C for up to 28 days. Compound integrity was analysed by size exclusion chromatography, nano differential scanning fluorimetry, UV–vis and dynamic light scattering. The analysis of the simultaneous binding of VEGF and Ang-2 was performed by grating-coupled interferometry. Additionally, samples were tested for sterility and presence of bacterial endotoxins. One-way ANOVA test was used to analyse statistical significance (p ≤ 0.05). Results No significant differences in VEGF and ANG-2 binding affinity were found in faricimab samples stored in either syringe type after 28 days compared to control. Chemical and physical stability testing revealed no statistically significant variation. Furthermore, sterility and the absence of bacterial endotoxins could be maintained. Conclusion Our findings confirm the pharmaceutical safety of compounded faricimab after storage for up to 28 days. This may facilitate a cost-effective off-label use of faricimab in clinical practice while maintaining safety in the treatment of patients.
- 4 December 2024
- Published by Springer Nature in Eye
- Vol. 39 (5) , 943-950
Faricimab maintains substance integrity and sterility after compounding and storage in two different polypropylene syringe types
Background Compounding and storage of intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents in syringes is commonly performed in an off-label manner. However, the preservation of compound integrity and microbiological safety must be guaranteed. The aim of this study was to compare the chemical and physical stability, sterility and binding affinity to vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) of faricimab, a novel bispecific anti-VEGF/Ang-2 biologic, after compounding and storage in two different polypropylene syringe types for up to 28 days. Methods Faricimab was compounded into silicone oil-free and silicone oil-containing polypropylene syringes under controlled aseptic clean room conditions and stored under light protection at 2–8 °C for up to 28 days. Compound integrity was analysed by size exclusion chromatography, nano differential scanning fluorimetry, UV–vis and dynamic light scattering. The analysis of the simultaneous binding of VEGF and Ang-2 was performed by grating-coupled interferometry. Additionally, samples were tested for sterility and presence of bacterial endotoxins. One-way ANOVA test was used to analyse statistical significance (p ≤ 0.05). Results No significant differences in VEGF and ANG-2 binding affinity were found in faricimab samples stored in either syringe type after 28 days compared to control. Chemical and physical stability testing revealed no statistically significant variation. Furthermore, sterility and the absence of bacterial endotoxins could be maintained. Conclusion Our findings confirm the pharmaceutical safety of compounded faricimab after storage for up to 28 days. This may facilitate a cost-effective off-label use of faricimab in clinical practice while maintaining safety in the treatment of patients.
- 3 September 2022
- Published by Taylor & Francis in Expert Review of Ophthalmology
- Vol. 17 (5) , 303-306
The future of biomarkers in neovascular age-related macular degeneration: active disease or degenerative process?
The introduction of intravitreal injections of anti-vascular endothelial growth factor (VEGF) has led to a new standard of care regarding the treatment of neovascular age-related macular degenerati...
- 3 September 2022
- Published by Taylor & Francis in Expert Review of Ophthalmology
- Vol. 17 (5) , 303-306
The future of biomarkers in neovascular age-related macular degeneration: active disease or degenerative process?
The introduction of intravitreal injections of anti-vascular endothelial growth factor (VEGF) has led to a new standard of care regarding the treatment of neovascular age-related macular degenerati...
- Open Access
- 11 August 2022
- Published by Springer Nature in Eye
- Vol. 37 (8) , 1750
Correction: Developing and validating a multivariable prediction model which predicts progression of intermediate to late age-related macular degeneration—the PINNACLE trial protocol
- 11 August 2022
- Published by Springer Nature in Eye
- Vol. 37 (8) , 1750
Open AccessCorrection: Developing and validating a multivariable prediction model which predicts progression of intermediate to late age-related macular degeneration—the PINNACLE trial protocol
- Open Access
- 25 May 2022
- Published by Springer Nature in Eye
- Vol. 37 (6) , 1275-1283
Developing and validating a multivariable prediction model which predicts progression of intermediate to late age-related macular degeneration—the PINNACLE trial protocol
Aims: Age-related macular degeneration (AMD) is characterised by a progressive loss of central vision. Intermediate AMD is a risk factor for progression to advanced stages categorised as geographic atrophy (GA) and neovascular AMD. However, rates of progression to advanced stages vary between individuals. Recent advances in imaging and computing technologies have enabled deep phenotyping of intermediate AMD. The aim of this project is to utilise machine learning (ML) and advanced statistical modelling as an innovative approach to discover novel features and accurately quantify markers of pathological retinal ageing that can individualise progression to advanced AMD. Methods: The PINNACLE study consists of both retrospective and prospective parts. In the retrospective part, more than 400,000 optical coherent tomography (OCT) images collected from four University Teaching Hospitals and the UK Biobank Population Study are being pooled, centrally stored and pre-processed. With this large dataset featuring eyes with AMD at various stages and healthy controls, we aim to identify imaging biomarkers for disease progression for intermediate AMD via supervised and unsupervised ML. The prospective study part will firstly characterise the progression of intermediate AMD in patients followed between one and three years; secondly, it will validate the utility of biomarkers identified in the retrospective cohort as predictors of progression towards late AMD. Patients aged 55–90 years old with intermediate AMD in at least one eye will be recruited across multiple sites in UK, Austria and Switzerland for visual function tests, multimodal retinal imaging and genotyping. Imaging will be repeated every four months to identify early focal signs of deterioration on spectral-domain optical coherence tomography (OCT) by human graders. A focal event triggers more frequent follow-up with visual function and imaging tests. The primary outcome is the sensitivity and specificity of the OCT imaging biomarkers. Secondary outcomes include sensitivity and specificity of novel multimodal imaging characteristics at predicting disease progression, ROC curves, time from development of imaging change to development of these endpoints, structure-function correlations, structure-genotype correlation and predictive risk models. Conclusions: This is one of the first studies in intermediate AMD to combine both ML, retrospective and prospective AMD patient data with the goal of identifying biomarkers of progression and to report the natural history of progression of intermediate AMD with multimodal retinal imaging.
- 25 May 2022
- Published by Springer Nature in Eye
- Vol. 37 (6) , 1275-1283
Open AccessDeveloping and validating a multivariable prediction model which predicts progression of intermediate to late age-related macular degeneration—the PINNACLE trial protocol
Aims: Age-related macular degeneration (AMD) is characterised by a progressive loss of central vision. Intermediate AMD is a risk factor for progression to advanced stages categorised as geographic atrophy (GA) and neovascular AMD. However, rates of progression to advanced stages vary between individuals. Recent advances in imaging and computing technologies have enabled deep phenotyping of intermediate AMD. The aim of this project is to utilise machine learning (ML) and advanced statistical modelling as an innovative approach to discover novel features and accurately quantify markers of pathological retinal ageing that can individualise progression to advanced AMD. Methods: The PINNACLE study consists of both retrospective and prospective parts. In the retrospective part, more than 400,000 optical coherent tomography (OCT) images collected from four University Teaching Hospitals and the UK Biobank Population Study are being pooled, centrally stored and pre-processed. With this large dataset featuring eyes with AMD at various stages and healthy controls, we aim to identify imaging biomarkers for disease progression for intermediate AMD via supervised and unsupervised ML. The prospective study part will firstly characterise the progression of intermediate AMD in patients followed between one and three years; secondly, it will validate the utility of biomarkers identified in the retrospective cohort as predictors of progression towards late AMD. Patients aged 55–90 years old with intermediate AMD in at least one eye will be recruited across multiple sites in UK, Austria and Switzerland for visual function tests, multimodal retinal imaging and genotyping. Imaging will be repeated every four months to identify early focal signs of deterioration on spectral-domain optical coherence tomography (OCT) by human graders. A focal event triggers more frequent follow-up with visual function and imaging tests. The primary outcome is the sensitivity and specificity of the OCT imaging biomarkers. Secondary outcomes include sensitivity and specificity of novel multimodal imaging characteristics at predicting disease progression, ROC curves, time from development of imaging change to development of these endpoints, structure-function correlations, structure-genotype correlation and predictive risk models. Conclusions: This is one of the first studies in intermediate AMD to combine both ML, retrospective and prospective AMD patient data with the goal of identifying biomarkers of progression and to report the natural history of progression of intermediate AMD with multimodal retinal imaging.
- 16 August 2021
- Published by Springer Nature in Eye
- Vol. 36 (10) , 2013-2019
Fundus autofluorescence and optical coherence tomography biomarkers associated with the progression of geographic atrophy secondary to age-related macular degeneration
Objectives To investigate the impact of qualitatively graded and deep learning quantified imaging biomarkers on growth of geographic atrophy (GA) secondary to age-related macular degeneration. Methods This prospective study included 1062 visits of 181 eyes of 100 patients with GA. Spectral-domain optical coherence tomography (SD-OCT) and fundus autofluorescence (FAF) images were acquired at each visit. Hyperreflective foci (HRF) were quantitatively assessed in SD-OCT volumes using a validated deep learning algorithm. FAF images were graded for FAF patterns, subretinal drusenoid deposits (SDD), GA lesion configuration and atrophy enlargement. Linear mixed models were calculated to investigate associations between all parameters and GA progression. Results FAF patterns were significantly associated with GA progression (p < 0.001). SDD was associated with faster GA growth (p = 0.005). Eyes with higher HRF concentrations showed a trend towards faster GA progression (p = 0.072) and revealed a significant impact on GA enlargement in interaction with FAF patterns (p = 0.01). The fellow eye status had no significant effect on lesion enlargement (p > 0.05). The diffuse-trickling FAF pattern exhibited significantly higher HRF concentrations than any other pattern (p < 0.001). Conclusion Among a wide range of investigated biomarkers, SDD and FAF patterns, particularly in interaction with HRF, significantly impact GA progression. Fully automated quantification of retinal imaging biomarkers such as HRF is both reliable and merited as HRF are indicators of retinal pigment epithelium dysmorphia, a central pathogenetic mechanism in GA. Identifying disease markers using the combination of FAF and SD-OCT is of high prognostic value and facilitates individualized patient management in a clinical setting.
- 16 August 2021
- Published by Springer Nature in Eye
- Vol. 36 (10) , 2013-2019
Fundus autofluorescence and optical coherence tomography biomarkers associated with the progression of geographic atrophy secondary to age-related macular degeneration
Objectives To investigate the impact of qualitatively graded and deep learning quantified imaging biomarkers on growth of geographic atrophy (GA) secondary to age-related macular degeneration. Methods This prospective study included 1062 visits of 181 eyes of 100 patients with GA. Spectral-domain optical coherence tomography (SD-OCT) and fundus autofluorescence (FAF) images were acquired at each visit. Hyperreflective foci (HRF) were quantitatively assessed in SD-OCT volumes using a validated deep learning algorithm. FAF images were graded for FAF patterns, subretinal drusenoid deposits (SDD), GA lesion configuration and atrophy enlargement. Linear mixed models were calculated to investigate associations between all parameters and GA progression. Results FAF patterns were significantly associated with GA progression (p < 0.001). SDD was associated with faster GA growth (p = 0.005). Eyes with higher HRF concentrations showed a trend towards faster GA progression (p = 0.072) and revealed a significant impact on GA enlargement in interaction with FAF patterns (p = 0.01). The fellow eye status had no significant effect on lesion enlargement (p > 0.05). The diffuse-trickling FAF pattern exhibited significantly higher HRF concentrations than any other pattern (p < 0.001). Conclusion Among a wide range of investigated biomarkers, SDD and FAF patterns, particularly in interaction with HRF, significantly impact GA progression. Fully automated quantification of retinal imaging biomarkers such as HRF is both reliable and merited as HRF are indicators of retinal pigment epithelium dysmorphia, a central pathogenetic mechanism in GA. Identifying disease markers using the combination of FAF and SD-OCT is of high prognostic value and facilitates individualized patient management in a clinical setting.
- 1 April 2021
- Published by Elsevier in Ophthalmology
- Vol. 128 (4) , e23-E23
Reply